Feasibility of Using 3D Ultrasound in Breast Cancer Screening of Women with High Risk.
Recruiting
- Conditions
- Breast carcinoma1000629110006232
- Registration Number
- NL-OMON31668
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
Women who are carriers of the BRCA-1 or BRCA-2 gene.
Exclusion Criteria
Bilateral breastamputation
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Main study parameter is the difference in detection performance between WBUS<br /><br>and mammography.<br /><br>Detection performance is measured by detection rate, specificity, and area<br /><br>under the ROC based on BIRADS scores.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Patient compliance.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What imaging biomarkers does 3D ultrasound detect in high-risk breast cancer screening (NL-OMON31668)?
How does 3D ultrasound compare to mammography and MRI in high-risk breast cancer detection (NL-OMON31668)?
Which genetic biomarkers (e.g., BRCA1/2) correlate with 3D ultrasound findings in NL-OMON31668 high-risk screening?
What are the safety profiles and false-positive rates of 3D ultrasound in NL-OMON31668 high-risk breast cancer screening?
How does 3D ultrasound sensitivity/specificity compare to contrast-enhanced mammography in high-risk breast cancer (NL-OMON31668)?